History
1892: The origins
MOLTENI FARMACEUTICI ’s history dates back to 1892, when in one of the oldest chemist shop of Florence, sterile ampoules for ipodermal use were created for the first time and commercialized two years later. This was the starting point of a renowned Italian pharmaceutical firm.
1991 - 1996: R&D Department foundation
In the 1991 Molteni founded his first R&D department to develop two projects (peptide analogues with analgesic properties and pure enantiomers of ibuprofen) strongly related with the pain therapy field, the main market of the company.
1996 - 2007: From the R&D project on PDT to Molteni Therapeutics
The R&D group started to work on new potential uses for PDT. The Molteni Group invested substantial resources in the effort and was able to secure some national financial grants available for innovative research on new photosensitizers. As a result of this effort, the R&D designed, screened and patented several new metal-phthalocyanine derivatives as PDT photosensitizers. The lead compound RLP068/Cl completed the preclinical phases and the results led to the decision by MOLTENI FARMACEUTICI to spin-off the project into a separate company: MOLTENI THERAPEUTICS S.r.l.
In 2006 new laboratories were opened and new researchers employed in order to carry on the work on the use of PDT for antimicrobial application and starting to focalize the use of the products in the treatment of infected wounds and skin ulcers.
2008 – 2011: Molteni Therapeutics "the Clinical challenge"
In 2009 Molteni Therapeutics performed the “first in human” clinical trial that showed safety and tolerability of the PDT treatment with RLP068/Cl formulated as a gel for topical administration.
In 2011 Molteni Therapeutics performed the “Proof of Concept” and demonstrated the efficacy and safety of topical application of RLP068/Cl in patients with infected diabetic foot ulcers.
2012: Molteni Therapeutics, a Medical Device company
The positive clinical results obtained with the lead compound RLP068/Cl in the treatment of foot ulcers in diabetic patients and the increased knowledge on the PDT proprietary substances played a role in the company evolution to a new phase dedicated to the development of innovative Medical Devices based on this photosensitizer. A certified business unit involved in design, production and trade of medical devices based on PDT agents was built. Since 2012 Molteni Therapeutics has a Quality Management System according to UNI ENI ISO 9001 & UNI CEI EN ISO 13485
2013-2014: VULNOFAST® products
In March 2013 Molteni Therapeutics obtained the CE Mark for the Medical Device VULNOFAST® gel.
In February 2014 Molteni Therapeutics obtained the CE Mark for the Medical Device VULNOLIGHT®, a proprietary light source.
In December 2014 Molteni Therapeutics obtained the CE Mark for the Medical Device VULNOFAST® plus, an industrialized dense liquid formulation.
